PCM
OVID icon

Prelude Capital Management’s Ovid Therapeutics OVID Stock Holding History

Prelude Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.3K Buy
+10,951
New +$19.6K ﹤0.01% 1156
2024
Q2 		– Sell
-25,555
Closed -$77.9K – 1417
2024
Q1 		$77.9K Buy
+25,555
New +$85.5K ﹤0.01% 1225

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Prelude Capital Management's OVID Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 10,951 shares worth $24.3K. The stake represents ﹤0.01% of the portfolio and ranks #1156 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in OVID as recently as Q1 2024.

Prelude Capital Management first reported a position in OVID in Q1 2024 and has held it in 2 quarters since. The position peaked at $77.9K in Q1 2024. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Prelude Capital Management held 10,951 shares of Ovid Therapeutics worth $24.3K as of Q1 2026.
  • Ovid Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1156 holding.
  • Prelude Capital Management first reported a position in Ovid Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • Prelude Capital Management's Ovid Therapeutics position peaked at $77.9K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.